Expansion of Pharmaceutical Manufacturing Capacity Through Acquisition of All Shares in the Sakura Plant Successor Company
First written in FY2020-Q1. 3 of 7 entries say "Advanced", first in FY2021-Q2. Latest entry: FY2024.
No other company in this theme has enough history to compare yet.
- FY2024AdvancedAnnual report
「At a meeting of the Board of Directors held on 27 November 2024, we resolved to carry out an absorption-type merger in which our consolidated subsidiary スペラファーマ株式会社 would be the surviving company and our consolidated subsidiary Iwaki Pharmaceutical Sakura Plant Co., Ltd. would be the absorbed company.」
In light of the Sakura Plant's expanded manufacturing capacity and its reclassification into the fine chemicals business, the company resolved to carry out an absorption-type merger scheduled for 1 June 2025, with スペラファーマ as the surviving company. The purpose is to optimize the CDMO business as a whole. - FY2024-Q1ReframedAnnual report
「From the first quarter of the current consolidated fiscal year, the Group changed the reportable segment of Iwaki Seiyaku Sakura Plant Co., Ltd. from the previous Pharmaceuticals business to the Fine Chemicals business, with the aim of accelerating growth in the Fine Chemicals business.」
The Sakura Plant's classification was changed from the pharmaceutical business to the fine chemicals business and reorganized to accelerate growth across the fine chemicals business, including business synergies with スペラファーマ and other companies. - FY2022-Q1RestatedAnnual report
「Iwaki Pharmaceutical Sakura Plant Co., Ltd. actively pursued requests for increased production of contract-manufactured products. As a result, contract-manufactured products continued to perform steadily.」
The Sakura Plant continued to respond to requests for increased production of contract-manufactured products, which performed steadily. - FY2021-Q3AdvancedAnnual report
「Iwaki Pharmaceutical Sakura Plant Co., Ltd. responded to new contract-manufacturing business and requests for increased production, and performed well.」
Following the acquisition of the Sakura Plant, the company made progress in securing new contract-manufacturing business and responding to requests for increased production, with the plant performing well. - FY2021-Q2AdvancedAnnual report
「At the Iwaki Pharmaceutical Sakura Plant, we actively pursued new contract-manufacturing business and requests for increased production. As a result, the plant performed well by responding to these requests and securing contract-manufacturing business.」
Following the acquisition of the Sakura Plant, the company pursued contract-manufacturing business and responded to requests for increased production, with the plant performing well. - FY2020-Q2AchievedAnnual report
「As a result, the acquisition of all shares was completed on 1 July 2020.」
The acquisition of all shares in Iwaki Pharmaceutical Sakura Plant Co., Ltd. was completed on 1 July 2020, executing the business combination aimed at strengthening manufacturing capacity for prescription pharmaceuticals. - FY2020-Q1First statedAnnual report
「Following a resolution by our Board of Directors at a meeting held on 18 March 2020 that our consolidated subsidiary Iwaki Pharmaceutical Co., Ltd. would acquire all shares in a newly established company scheduled to take over the Sakura Plant from Torii Pharmaceutical Co., Ltd. through a company split, we entered into a share transfer agreement with Iwaki Pharmaceutical and Torii Pharmaceutical on the same date.」
Iwaki Pharmaceutical entered into an agreement to acquire all shares in the newly established company taking over the Sakura Plant. The business combination was scheduled for 1 July 2020, with estimated acquisition costs of ¥1,100 million. The objectives were to strengthen manufacturing capacity for prescription pharmaceuticals and create complementarity and synergies with existing businesses.